Comorbidity and polypharmacy in elderly cancer patients: The significance on treatment outcome and tolerance

Trine Lembrecht Jørgensen; Jesper Hallas; Lotte Holm Land; Jørn Herrstedt

doi:10.1016/j.jgo.2010.06.003

Comorbidity and polypharmacy in elderly cancer patients: The significance on treatment outcome and tolerance

Trine Lembrecht Jørgensen^*, Jesper Hallas, Lotte Holm Land, Jørn Herrstedt

^*Corresponding author af dette arbejde

Publikation: Bidrag til tidsskrift › Review › Forskning › peer review

Abstract

Older adults have an increased burden of comorbidity which increases their risk of being exposed to polypharmacy. Because of underrepresentation of elderly cancer patients in clinical trials, knowledge of the influence of comorbidity and polypharmacy on these patients' response and tolerance to antineoplastic treatment is sparse. We reviewed the literature on comorbidity and polypharmacy in elderly cancer patients and the impact of these factors on treatment outcome. Large population-based studies all found an association between comorbidity and survival among elderly cancer patients. However, we need to focus on cancer-specific survival to conclude on the influence of comorbidity on cancer disease and its treatment. Prospective studies are needed to conclude on the influence of comorbidity and polypharmacy on treatment tolerance and response to antineoplastic treatment.

Originalsprog	Engelsk
Sider (fra-til)	87-102
Antal sider	16
Tidsskrift	Journal of Geriatric Oncology
Vol/bind	1
Udgave nummer	2
DOI	https://doi.org/10.1016/j.jgo.2010.06.003
Status	Udgivet - 1 okt. 2010

Adgang til dokumentet

10.1016/j.jgo.2010.06.003

Andre filer og links

http://www.scopus.com/inward/record.url?scp=77957891719&partnerID=8YFLogxK

Citationsformater

@article{df42a453589e487fb4a13766a657af9d,

title = "Comorbidity and polypharmacy in elderly cancer patients: The significance on treatment outcome and tolerance",

abstract = "Older adults have an increased burden of comorbidity which increases their risk of being exposed to polypharmacy. Because of underrepresentation of elderly cancer patients in clinical trials, knowledge of the influence of comorbidity and polypharmacy on these patients' response and tolerance to antineoplastic treatment is sparse. We reviewed the literature on comorbidity and polypharmacy in elderly cancer patients and the impact of these factors on treatment outcome. Large population-based studies all found an association between comorbidity and survival among elderly cancer patients. However, we need to focus on cancer-specific survival to conclude on the influence of comorbidity on cancer disease and its treatment. Prospective studies are needed to conclude on the influence of comorbidity and polypharmacy on treatment tolerance and response to antineoplastic treatment.",

keywords = "Chemotherapy, Comorbidity, Geriatric assessment, Geriatric oncology, Polypharmacy, Supportive care, Treatment outcome, Treatment tolerance",

author = "J{\o}rgensen, {Trine Lembrecht} and Jesper Hallas and Land, {Lotte Holm} and J{\o}rn Herrstedt",

year = "2010",

month = oct,

day = "1",

doi = "10.1016/j.jgo.2010.06.003",

language = "English",

volume = "1",

pages = "87--102",

journal = "Journal of Geriatric Oncology",

issn = "1879-4068",

publisher = "Elsevier",

number = "2",

}

TY - JOUR

T1 - Comorbidity and polypharmacy in elderly cancer patients

T2 - The significance on treatment outcome and tolerance

AU - Jørgensen, Trine Lembrecht

AU - Hallas, Jesper

AU - Land, Lotte Holm

AU - Herrstedt, Jørn

PY - 2010/10/1

Y1 - 2010/10/1

N2 - Older adults have an increased burden of comorbidity which increases their risk of being exposed to polypharmacy. Because of underrepresentation of elderly cancer patients in clinical trials, knowledge of the influence of comorbidity and polypharmacy on these patients' response and tolerance to antineoplastic treatment is sparse. We reviewed the literature on comorbidity and polypharmacy in elderly cancer patients and the impact of these factors on treatment outcome. Large population-based studies all found an association between comorbidity and survival among elderly cancer patients. However, we need to focus on cancer-specific survival to conclude on the influence of comorbidity on cancer disease and its treatment. Prospective studies are needed to conclude on the influence of comorbidity and polypharmacy on treatment tolerance and response to antineoplastic treatment.

AB - Older adults have an increased burden of comorbidity which increases their risk of being exposed to polypharmacy. Because of underrepresentation of elderly cancer patients in clinical trials, knowledge of the influence of comorbidity and polypharmacy on these patients' response and tolerance to antineoplastic treatment is sparse. We reviewed the literature on comorbidity and polypharmacy in elderly cancer patients and the impact of these factors on treatment outcome. Large population-based studies all found an association between comorbidity and survival among elderly cancer patients. However, we need to focus on cancer-specific survival to conclude on the influence of comorbidity on cancer disease and its treatment. Prospective studies are needed to conclude on the influence of comorbidity and polypharmacy on treatment tolerance and response to antineoplastic treatment.

KW - Chemotherapy

KW - Comorbidity

KW - Geriatric assessment

KW - Geriatric oncology

KW - Polypharmacy

KW - Supportive care

KW - Treatment outcome

KW - Treatment tolerance

UR - http://www.scopus.com/inward/record.url?scp=77957891719&partnerID=8YFLogxK

U2 - 10.1016/j.jgo.2010.06.003

DO - 10.1016/j.jgo.2010.06.003

M3 - Review

AN - SCOPUS:77957891719

SN - 1879-4068

VL - 1

SP - 87

EP - 102

JO - Journal of Geriatric Oncology

JF - Journal of Geriatric Oncology

IS - 2

ER -

Comorbidity and polypharmacy in elderly cancer patients: The significance on treatment outcome and tolerance

Abstract

Adgang til dokumentet

Andre filer og links

Fingeraftryk

Citationsformater